SCHEMBL7725709

SCHEMBL7725709

CC(C)(C)OC(=O)N1C[C@H](N(C(=O)CN)C(=O)OC(C)(C)C)C[C@H]1C(=O)Nc1ccc(C(C)(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.43
POLB P06746 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD11B1 P28845 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HDAC8 Q9BY41 5/20 0.39
ABL1 P00519 4/20 0.38
BCR P11274 4/20 0.38
PTPN1 P18031 3/20 0.38
PTPN2 P17706 1/20 0.38
PTPN6 P29350 1/20 0.38
F13A1 P00488 1/20 0.36
TGM2 P21980 1/20 0.36
TGM1 P22735 1/20 0.36
HTRA1 Q92743 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7728192 0.91 POLB (0.47) NPC1POLBCYP1A2CYP3A4CYP2C19
SCHEMBL7731725 0.89 HDAC8 (0.44) NPC1POLBCYP1A2CYP3A4CYP2C19
SCHEMBL7731479 0.88 HDAC8 (0.44) NPC1POLBCYP1A2CYP3A4CYP2C19
SCHEMBL7726523 0.88 HDAC8 (0.41) NPC1POLBCYP1A2CYP3A4CYP2C19
SCHEMBL7727754 0.87 POLB (0.44) NPC1POLBCYP1A2CYP3A4CYP2C19
SCHEMBL7727252 0.85 KDM4E (0.46) NPC1POLBHDAC8MAPT
SCHEMBL7729236 0.81 HDAC4 (0.41) NPC1POLBCYP1A2CYP3A4CYP2C19
SCHEMBL7728738 0.80 KDM4E (0.46) POLBMEN1KMT2AMAPT
SCHEMBL7722105 0.80 PTPN1 (0.40) NPC1POLBCYP1A2CYP3A4CYP2C19
SCHEMBL7726393 0.80 PTPN1 (0.39) POLBCYP1A2CYP3A4CYP2C19HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6399629-B1 PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY MICROCIDE PHARMACEUTICALS, INC. 2002-06-04 US disclosed